U.S. Markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.98-0.15 (-1.24%)
At close: 4:00PM EDT

11.98 0.00 (0.00%)
After hours: 4:14PM EDT

People also watch
GNVCCRISIMMUBCRXLJPC
  • J
    Joe West
    Joe West
    Evercore ISI Initiates Coverage on Insmed in a research report with an outperform rating and a $28.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research raised shares of Insmed from a hold rating to a buy rating and set a $19.00 price target HC Wainwright reaffirmed a buy rating on shares of Insmed Stifel Nicolaus increased their price target on shares of Insmed from $23.00 to $27.00 and gave the company a buy rating iValuEngine raised shares of Insmed from a sell rating to a hold rating Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. Insmed has an average rating of Hold and an average price target of $23.00.
  • C
    Cindy
    Cindy
    Insmed no longer has a short stature approval as the corresponding maturing site and the drug process no longer exist {expired} iPLEX failed ALS Insmeds last shot They sold all rights to the retinopathy of prematurity to shire al that trial failed.iplex has a dismal record of failure and no company is going to spend millions and years ( FDA mfg approval} to trial.a different indication.Its a red herring Insmed is about Arikayce only
  • K
    Kinky
    Kinky
    Now this is funny!\ from guess where?\""results are released, and for less than we where getting 60 days ago..So when this happens, we will all know who's behind this bear raid, and who we should consider suing." \
    First report it to the SEC!\and standby !\ then wait for some shyster to sue Insmeds management !\ Now thats a lawsuit I want to see! \ Sue because the SP fell!
    Treasury bills for you only!\
  • F
    Fghyujk Sdfghj
    Fghyujk Sdfghj
    Traders had fun yesterday with "President Trump to visit Insmed headquarters!
    With the Trump golf course close by and Trumps current residence in Bridgewater N.J a great photo opp and a great chance to unload every single share
  • Z
    Zorro
    Zorro
    2nd quarter numbers =Increased Positions 67 4,889,844
    Decreased Positions 41 2,934,744
    Held Positions 17 51,177,882
    Total Institutional Shares 125 59,002,470
    I agree this was all before the attack
  • P
    Predict
    Predict
    So does retail lose and the big time money make a fortune?Are those free options 10x more valuable then any stock management may own? Are they willing to take a cheap takeover price to a large pharma? If the results were reported tomorrow would the stock shoot up 50% to $18? Biotech has scrwd me again
  • l
    linda
    linda
    Anyone have any buys by the top Institutions SINCE June 30? Why haven't they added?
  • P
    Predict
    Predict
    June 30th data .The second quarter had buyers in the $17 to $18 dollar range.The sellers came 2 months later. what changed?Listen to Insmeds last presentation.W.Lewis and every one in management couched their comments in caution IF hope etc. I dont buy conspiracy theories.
  • K
    Kinky
    Kinky
    Why do all analst recc the price that I sold at 2 years ago and then went short to the price we are at now? \Coincidence?\ I think not
  • K
    Kinky
    Kinky
    The poor idiotvillage investors don't get why Sales jobs are not hires\ THEY ARE CONTINGENT ON GETTING AN APPROVED DRUG TO SELL \hopefully by eoy 2018
  • A
    Ashley
    Ashley
    In the short-term INSM does not seem to be like a good trade. Ive been struggling with this stock lately. Some of my other trades have been from awe-some*sto-cks which are working out pretty well.
  • K
    Kinky
    Kinky
    Register your complaint with the SEC today! LOL for what? !\ investorvillage squirrels
  • J
    Jennifer
    Jennifer
    My guess is that INSM is due for a pullback in the short-run. awe-some*sto-cks just allerted a new stock - it beats having to dig online yourself for new stock ideas.
  • l
    linda
    linda
    So today is a good day?Volume seems to be drying up but are they finished?Painful for longs.Some mention of 2nd Quarter activity but that was 6 weeks ago+ $17.25 -18. Are the biggest owners of Insmed planning a dilution down here again? A placement could be done to only "strategic owners" {2/3rds owed by just 6 funds}
  • t
    tom
    tom
    Linda is a loser. Will have to turn to hooking!
  • K
    Kinky
    Kinky
    $11.54 please
  • Z
    Zorro
    Zorro
    So its a plot if there is a big seller who thinks the trials may be bad and is dumping?
    There is a seller and the shares are real IV is full of idiots Stop posting about them
  • K
    Kinky
    Kinky
    Google Linhaliq +NTM \which is the better short term trade for a double?\ INSM or ARDM \after a sell on the news ARDM is up 40% in the last 2 weeks
  • K
    Kinky
    Kinky
    ARDM -FDA GIVES OK TO FILE AFTER REVIEWING THEIR PHASE3 TRIAL UP 18% INVESTORS PILING IN announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infections with Pseudomonas aeruginosa (P. aeruginosa).
  • l
    linda
    linda
    Aradigm is not a direct competitor and their market may come under the umbrella of respiratory treatments.The FDA it appears found Aradigm to be quite convincing.Based on Arardigms NTM patent and FDA discussions =if successful with Pulmaquin [inhaled ciprofloxacin} non-cystic fibrosis bronchiectasis (BE). Aradigm who already has spoken to investors about CF may be Insmeds worst dream[NTM] .Give them their due =Aradigm is one of those bios that emerges from the ashes of biotech failures We shall see how they do but short term could be a pretty good investment